Jacalyn Rosenblatt
Overview
Explore the profile of Jacalyn Rosenblatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2714
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung D, Shah N, Wu J, Logan B, Bisharat L, Callander N, et al.
Clin Cancer Res
. 2024 Oct;
30(19):4542.
PMID: 39350638
No abstract available.
2.
Derman B, Cooperrider J, Rosenblatt J, Avigan D, Rampurwala M, Barnidge D, et al.
Blood Cancer J
. 2024 May;
14(1):87.
PMID: 38811560
We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K), lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in newly diagnosed...
3.
Pilcher W, Yao L, Gonzalez-Kozlova E, Pita-Juarez Y, Karagkouni D, Acharya C, et al.
bioRxiv
. 2024 May;
PMID: 38798338
Multiple Myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence...
4.
Avigan Z, Dias A, Dodge L, Arnason J, Joyce R, Liegel J, et al.
Transfusion
. 2024 May;
64(6):1068-1075.
PMID: 38693089
Background: CD34+ stem cells serve as the primary graft source for allogeneic transplants, with a minimum of 2-4 × 10 cells/kg needed for engraftment. There are conflicting data on outcomes...
5.
ODonnell E, Mo C, Yee A, Nadeem O, Laubach J, Rosenblatt J, et al.
Lancet Haematol
. 2024 Apr;
11(6):e415-e424.
PMID: 38677302
Background: Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone...
6.
Pophali P, Varela J, Rosenblatt J
Front Oncol
. 2024 Feb;
14:1323914.
PMID: 38322418
Malignant cells are known to evade immune surveillance by engaging immune checkpoints which are negative regulators of the immune system. By restoring the T-lymphocyte mediated anti-tumor effect, immune checkpoint inhibitors...
7.
Lin Y, Raje N, Berdeja J, Siegel D, Jagannath S, Madduri D, et al.
Nat Med
. 2023 Aug;
29(9):2286-2294.
PMID: 37592106
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple...
8.
Chung D, Shah N, Wu J, Logan B, Bisharat L, Callander N, et al.
Clin Cancer Res
. 2023 Jul;
29(23):4784-4796.
PMID: 37463058
Purpose: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell...
9.
Koshy A, Kim H, Liegel J, Arnason J, Ho V, Antin J, et al.
Blood
. 2023 Mar;
141(24):2932-2943.
PMID: 36862975
Steroid-refractory chronic graft-versus-host disease (cGVHD) after allogeneic transplant remains a significant cause of morbidity and mortality. Abatacept is a selective costimulation modulator, used for the treatment of rheumatologic diseases, and...
10.
Boussi L, Avigan Z, Rosenblatt J
Front Immunol
. 2022 Nov;
13:1027385.
PMID: 36389674
Despite advances in treatment for multiple myeloma, the majority of patients ultimately develop relapsed disease marked by immune evasion and resistance to standard therapy. Immunotherapy has emerged as a powerful...